These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 22161940)

  • 21. A randomized, controlled trial of cognitive-behavioral therapy for augmenting pharmacotherapy in obsessive-compulsive disorder.
    Simpson HB; Foa EB; Liebowitz MR; Ledley DR; Huppert JD; Cahill S; Vermes D; Schmidt AB; Hembree E; Franklin M; Campeas R; Hahn CG; Petkova E
    Am J Psychiatry; 2008 May; 165(5):621-30. PubMed ID: 18316422
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cognitive behavior therapy augmentation of pharmacotherapy in pediatric obsessive-compulsive disorder: the Pediatric OCD Treatment Study II (POTS II) randomized controlled trial.
    Franklin ME; Sapyta J; Freeman JB; Khanna M; Compton S; Almirall D; Moore P; Choate-Summers M; Garcia A; Edson AL; Foa EB; March JS
    JAMA; 2011 Sep; 306(11):1224-32. PubMed ID: 21934055
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Refractory obsessive-compulsive disorder: state-of-the-art treatment.
    Hollander E; Bienstock CA; Koran LM; Pallanti S; Marazziti D; Rasmussen SA; Ravizza L; Benkelfat C; Saxena S; Greenberg BD; Sasson Y; Zohar J
    J Clin Psychiatry; 2002; 63 Suppl 6():20-9. PubMed ID: 12027116
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of Augmentation of Cognitive Behavior Therapy With Weight-Adjusted d-Cycloserine vs Placebo in Pediatric Obsessive-Compulsive Disorder: A Randomized Clinical Trial.
    Storch EA; Wilhelm S; Sprich S; Henin A; Micco J; Small BJ; McGuire J; Mutch PJ; Lewin AB; Murphy TK; Geller DA
    JAMA Psychiatry; 2016 Aug; 73(8):779-88. PubMed ID: 27367832
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Clinical features of patients with obsessive-compulsive disorder showing different pharmacological responses].
    Sumitani S; Ueno S; Ishimoto Y; Taniguchi T; Tomotake M; Motoki I; Yamauchi K; Ohmori T
    Seishin Shinkeigaku Zasshi; 2006; 108(12):1282-92. PubMed ID: 17334085
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New developments in the treatment of obsessive-compulsive disorder.
    Leonard HL
    J Clin Psychiatry; 1997; 58 Suppl 14():39-45; discussion 46-7. PubMed ID: 9418745
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Issues in the pharmacological treatment of obsessive-compulsive disorder.
    Math SB; Janardhan Reddy YC
    Int J Clin Pract; 2007 Jul; 61(7):1188-97. PubMed ID: 17511795
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early onset of response with selective serotonin reuptake inhibitors in obsessive-compulsive disorder: a meta-analysis.
    Issari Y; Jakubovski E; Bartley CA; Pittenger C; Bloch MH
    J Clin Psychiatry; 2016 May; 77(5):e605-11. PubMed ID: 27249090
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder.
    Foa EB; Liebowitz MR; Kozak MJ; Davies S; Campeas R; Franklin ME; Huppert JD; Kjernisted K; Rowan V; Schmidt AB; Simpson HB; Tu X
    Am J Psychiatry; 2005 Jan; 162(1):151-61. PubMed ID: 15625214
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A single-blinded case-control study of memantine in severe obsessive-compulsive disorder.
    Stewart SE; Jenike EA; Hezel DM; Stack DE; Dodman NH; Shuster L; Jenike MA
    J Clin Psychopharmacol; 2010 Feb; 30(1):34-9. PubMed ID: 20075645
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder.
    Pigott TA; Seay SM
    J Clin Psychiatry; 1999 Feb; 60(2):101-6. PubMed ID: 10084636
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial.
    Simpson HB; Foa EB; Liebowitz MR; Huppert JD; Cahill S; Maher MJ; McLean CP; Bender J; Marcus SM; Williams MT; Weaver J; Vermes D; Van Meter PE; Rodriguez CI; Powers M; Pinto A; Imms P; Hahn CG; Campeas R
    JAMA Psychiatry; 2013 Nov; 70(11):1190-9. PubMed ID: 24026523
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [To identify and treat obsessive-compulsive disorders: an overview].
    Voderholzer U; Hauer M; Stattrop U
    MMW Fortschr Med; 2013 Sep; 155(15):37-9. PubMed ID: 24224373
    [No Abstract]   [Full Text] [Related]  

  • 34. Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial.
    Pediatric OCD Treatment Study (POTS) Team
    JAMA; 2004 Oct; 292(16):1969-76. PubMed ID: 15507582
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacotherapy for obsessive compulsive disorder in clinical practice - Data of 842 inpatients from the International AMSP Project between 1994 and 2012.
    Poppe C; Müller ST; Greil W; Walder A; Grohmann R; Stübner S
    J Affect Disord; 2016 Aug; 200():89-96. PubMed ID: 27130958
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series.
    Weiss EL; Potenza MN; McDougle CJ; Epperson CN
    J Clin Psychiatry; 1999 Aug; 60(8):524-7. PubMed ID: 10485634
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Commonly asked questions in the treatment of obsessive-compulsive disorder.
    Arumugham SS; Reddy YC
    Expert Rev Neurother; 2014 Feb; 14(2):151-63. PubMed ID: 24372473
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A meta-analysis of dropout rates from exposure with response prevention and pharmacological treatment for youth with obsessive compulsive disorder.
    Johnco C; McGuire JF; Roper T; Storch EA
    Depress Anxiety; 2020 May; 37(5):407-417. PubMed ID: 31778595
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Atypical antipsychotic augmentation in SSRI treatment refractory obsessive-compulsive disorder: a systematic review and meta-analysis.
    Veale D; Miles S; Smallcombe N; Ghezai H; Goldacre B; Hodsoll J
    BMC Psychiatry; 2014 Nov; 14():317. PubMed ID: 25432131
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An update on the pharmacological treatment of obsessive-compulsive disorder.
    Fontenelle LF; Nascimento AL; Mendlowicz MV; Shavitt RG; Versiani M
    Expert Opin Pharmacother; 2007 Apr; 8(5):563-83. PubMed ID: 17376013
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.